<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452372</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-AS1-001</org_study_id>
    <nct_id>NCT02452372</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)</brief_title>
  <official_title>A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of givosiran (ALN-AS1)
      in AIP patients as well as to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of
      ALN-AS1 in AIP patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of givosiran evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), and AEs leading to study drug discontinuation</measure>
    <time_frame>Part A (SAD phase): through day 42; Part B (MAD) phase: through Day 70; Part C (MD) phase: through Day 168</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of givosiran</measure>
    <time_frame>Part A (SAD) phase: predose - 42 days post-dose; Part B (MAD) phase: predose - 70 days post-dose; Part C (MD) phase: predose - 168 days post-dose</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of givosiran</measure>
    <time_frame>Part A (SAD) phase: predose - 42 days post-dose; Part B (MAD) phase: predose - 70 days post-dose; Part C (MD) phase: predose - 168 days post-dose</time_frame>
    <description>tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of givosiran</measure>
    <time_frame>Part A (SAD) phase: predose - 42 days post-dose; Part B (MAD) phase: predose - 70 days post-dose; Part C (MD) phase: predose - 168 days post-dose</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics (PK) of givosiran</measure>
    <time_frame>Part A (SAD) phase: predose - 42 days post-dose; Part B (MAD) phase: predose - 70 days post-dose; Part C (MD) phase: predose - 168 days post-dose</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in delta-aminolevulinic acid (ALA) from baseline</measure>
    <time_frame>Part A (SAD) phase: screening - 42 days post-dose; Part B (MAD) phase: screening - 70 days post-dose; Part C (MD) phase: screening - 168 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Porphobilinogen (PBG) from baseline</measure>
    <time_frame>Part A (SAD) phase: screening - 42 days post-dose; Part B (MAD) phase: screening - 70 days post-dose; Part C (MD) phase: screening - 168 days post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Intermittent Porphyria</condition>
  <arm_group>
    <arm_group_label>givosiran (ALN-AS1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>givosiran (ALN-AS1)</intervention_name>
    <description>Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection</description>
    <arm_group_label>givosiran (ALN-AS1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>calculated volume to match active comparator</description>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Parts A and B

        Inclusion Criteria:

          -  Diagnosis of AIP

          -  Urine PBG at Screening indicating patient is a high excreter

          -  No clinically significant health concerns

          -  Women of child bearing potential must have a negative pregnancy test, not be nursing,
             and use effective contraception

          -  Willing to provide written informed consent and willing to comply with study
             requirements.

        Exclusion Criteria:

          -  Porphyria attack within 6 months of screening

          -  Started a new prescription medication within 3 months of screening

          -  Clinically significant abnormal laboratory results

          -  Received an investigational agent within 90 days before the first dose of study drug
             or are in follow-up of another clinical study

          -  History of multiple drug allergies or intolerance to subcutaneous injection

        Part C

        Inclusion Criteria:

          -  Diagnosis of AIP

          -  Patient experienced a porphyria attack or was taking medication to prevent attacks
             recently

          -  No clinically significant health concerns

          -  Women of child bearing potential must have a negative pregnancy test, not be nursing,
             and use effective contraception

          -  Willing to provide written informed consent and willing to comply with study
             requirements.

        Exclusion Criteria:

          -  Stared a new prescription medication within 3 months of screening

          -  Clinically significant abnormal laboratory results

          -  Received an investigational agent within 90 days before the first dose of study drug
             or are in follow-up of another clinical study

          -  History of multiple drug allergies or intolerance to subcutaneous injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Simon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RNAi therapeutic</keyword>
  <keyword>Porphyria</keyword>
  <keyword>AIP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyrias</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Porphyria, Acute Intermittent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

